Loading clinical trials...
Loading clinical trials...
A Phase 1 Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors for Epidermal Growth Factor Receptor (EGFR)-Mutant Advanced Non-small Cell Lung Cancer
Conditions
Interventions
CurcuVIVA™
Tyrosine Kinase Inhibitor gefitinib (Iressa)
+1 more
Locations
1
Canada
Peter Brojge Lung Cancer Center, Jewish General Hospital
Montreal, Quebec, Canada
Start Date
August 1, 2015
Primary Completion Date
August 1, 2016
Completion Date
December 1, 2016
Last Updated
September 2, 2015
NCT06498635
NCT05198830
NCT06066138
NCT05692635
NCT06305754
NCT07485114
Lead Sponsor
Lady Davis Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions